Brinker Capital Inc. Sells 165 Shares of ResMed Inc. (RMD)
Brinker Capital Inc. lessened its holdings in ResMed Inc. (NYSE:RMD) by 6.2% during the fourth quarter, HoldingsChannel.com reports. The firm owned 2,513 shares of the medical equipment provider’s stock after selling 165 shares during the quarter. Brinker Capital Inc.’s holdings in ResMed were worth $286,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds have also made changes to their positions in the business. Vanguard Group Inc lifted its stake in shares of ResMed by 0.5% in the third quarter. Vanguard Group Inc now owns 14,567,805 shares of the medical equipment provider’s stock worth $1,680,251,000 after buying an additional 69,129 shares in the last quarter. BlackRock Inc. lifted its stake in shares of ResMed by 5.2% in the fourth quarter. BlackRock Inc. now owns 11,764,243 shares of the medical equipment provider’s stock worth $1,339,597,000 after buying an additional 583,831 shares in the last quarter. Oregon Public Employees Retirement Fund lifted its stake in shares of ResMed by 15,868.5% in the fourth quarter. Oregon Public Employees Retirement Fund now owns 5,275,028 shares of the medical equipment provider’s stock worth $46,000 after buying an additional 5,241,994 shares in the last quarter. Baillie Gifford & Co. lifted its stake in shares of ResMed by 0.3% in the third quarter. Baillie Gifford & Co. now owns 4,841,478 shares of the medical equipment provider’s stock worth $558,416,000 after buying an additional 14,627 shares in the last quarter. Finally, WCM Investment Management LLC bought a new position in shares of ResMed in the fourth quarter worth approximately $492,415,000. Institutional investors and hedge funds own 68.12% of the company’s stock.
Shares of ResMed stock opened at $102.70 on Friday. The company has a market cap of $14.66 billion, a P/E ratio of 29.09, a P/E/G ratio of 2.72 and a beta of 0.58. ResMed Inc. has a twelve month low of $90.64 and a twelve month high of $118.50. The company has a debt-to-equity ratio of 0.61, a quick ratio of 1.76 and a current ratio of 2.44.
The business also recently disclosed a quarterly dividend, which was paid on Thursday, March 14th. Investors of record on Thursday, February 7th were given a dividend of $0.37 per share. The ex-dividend date of this dividend was Wednesday, February 6th. This represents a $1.48 dividend on an annualized basis and a yield of 1.44%. ResMed’s dividend payout ratio (DPR) is 41.93%.
In related news, CEO Michael J. Farrell sold 6,651 shares of the stock in a transaction that occurred on Monday, January 14th. The shares were sold at an average price of $113.75, for a total transaction of $756,551.25. Following the transaction, the chief executive officer now owns 292,933 shares in the company, valued at $33,321,128.75. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider James Hollingshead sold 1,600 shares of the stock in a transaction that occurred on Wednesday, January 2nd. The stock was sold at an average price of $112.13, for a total transaction of $179,408.00. Following the completion of the transaction, the insider now owns 84,489 shares in the company, valued at $9,473,751.57. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 77,205 shares of company stock worth $7,980,737. 1.24% of the stock is owned by insiders.
Several research analysts have recently issued reports on the stock. BMO Capital Markets dropped their target price on shares of ResMed to $120.00 and set a “positive” rating on the stock in a research note on Monday, January 28th. Deutsche Bank upgraded shares of ResMed from a “hold” rating to a “buy” rating in a research note on Wednesday, March 20th. Goldman Sachs Group downgraded shares of ResMed from a “buy” rating to a “neutral” rating in a research note on Friday, January 25th. Finally, JPMorgan Chase & Co. downgraded shares of ResMed from a “neutral” rating to an “underweight” rating and set a $99.60 target price on the stock. in a research note on Friday, January 25th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and four have given a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus target price of $113.20.
ResMed Company Profile
ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep disordered breathing, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, portable oxygen concentrators, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes.
Recommended Story: What are the most popular ETFs
Want to see what other hedge funds are holding RMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ResMed Inc. (NYSE:RMD).
Receive News & Ratings for ResMed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ResMed and related companies with MarketBeat.com's FREE daily email newsletter.